ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada
Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04225910 (Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
Who cites it
8 citing papers in PubMed.
- Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration-Resistant Prostate Cancer.Clinical pharmacology and therapeutics · 2022Article
- Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.Translational andrology and urology · 2019Article
- Article
- Current approaches to incorporation of radium-223 in clinical practice.Prostate cancer and prostatic diseases · 2018Review
- Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.World journal of clinical oncology · 2015Article
- Optimal management of patients receiving cabazitaxel-based chemotherapy.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
- Chemotherapy for prostate cancer: Clinical practice in Canada.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
- Metastatic castration-resistant prostate cancer: The emerging continuum of care.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are currently two medical treatments approved in Canada that offer survival benefits for patients with metastatic castration-resistant prostate cancer that progresses on or after docetaxel-based chemotherapy, and evidence is accumulating on the efficacy of further interventions in this setting. The current and emerging strategies are based on a variety of mechanisms (cytotoxicity, hormonal inhibition, radiopharmacy and immunotherapy) and there is nothing to suggest that patients will be unable to benefit from several or even all of these agents when used sequentially. Given the possibility of multiple lines of treatment for patients whose disease progresses on or after docetaxel, the challenge for clinicians will be to determine the optimum treatment pathway for each individual. That challenge is already being faced, albeit on a limited scale, now that both cabazitaxel (chemotherapy) and abiraterone (hormonal agent) are available for use post-docetaxel.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.